On Tuesday, the Drugs Controller General of India (DCGI) granted emergency use authorisation to Novavax Covid-19 vaccine Covovax for use on teenagers aged between 12 and 17. The vaccine, also known as NVX-CoV2373, is manufactured by the Serum Institute of India under the brand name Covovax. Last month, Novavax conducted the last stage trial of the vaccine on 2,247 Indian teenagers aged between 12 and 17, which returned an 80% efficacy rate. Novavax also ran phase three trials of Covovax in the United States and the United Kingdom on participants aged 18 years and older, which showed an efficacy rate of 90.4% and 89.7%, respectively.

-----

The Article is published first on Wikinews.org on Thursday, March 24, 2022